Victory Capital Management
ADMS

Victory Capital Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Victory Capital Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-973
Closed -$7K – 1874
2019
Q1 		$7K Hold
973
– – ﹤0.01% 1769
2018
Q4 		$8K Hold
973
– – ﹤0.01% 1772
2018
Q3 		$19K Buy
973
+128
+15% +$3.01K ﹤0.01% 1762
2018
Q2 		$22K Hold
845
– – ﹤0.01% 1792
2018
Q1 		$20K Hold
845
– – ﹤0.01% 1792
2017
Q4 		$29K Hold
845
– – ﹤0.01% 1773
2017
Q3 		$18K Sell
845
-593
-41% -$10.9K ﹤0.01% 1782
2017
Q2 		$25K Buy
1,438
+25
+2% +$413 ﹤0.01% 1766
2017
Q1 		$25K Buy
1,413
+351
+33% +$5.98K ﹤0.01% 1756
2016
Q4 		$18K Buy
1,062
+60
+6% +$928 ﹤0.01% 1765
2016
Q3 		$16K Buy
1,002
+67
+7% +$1.02K ﹤0.01% 1761
2016
Q2 		$14K Buy
935
+179
+24% +$2.95K ﹤0.01% 1611
2016
Q1 		$11K Buy
756
+59
+8% +$994 ﹤0.01% 1646
2015
Q4 		$20K Buy
697
+37
+6% +$623 ﹤0.01% 1648
2015
Q3 		$11K Buy
660
+57
+9% +$1.3K ﹤0.01% 1605
2015
Q2 		$16K Buy
+603
New +$11.7K ﹤0.01% 1606

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Victory Capital Management's ADMS Position: Q2 2019 in Review

Victory Capital Management sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 973 shares — an estimated $7K sold.

Victory Capital Management first reported a position in ADMS in Q2 2015 and held it in 16 quarters. The position peaked at $29K in Q4 2017. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • Victory Capital Management reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Victory Capital Management sold 973 Adamas Pharmaceuticals shares in Q2 2019, an estimated $7K.
  • Victory Capital Management first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 16 quarters.
  • Victory Capital Management's Adamas Pharmaceuticals position peaked at $29K in Q4 2017.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on Victory Capital Management's 13F filing for Q2 2019, filed 15 Aug 2019.